{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-241397","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2024-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.032187+00:00","generated_at":"2026-05-30T11:06:16.891995+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RMC-6236 shows 8.5-month median PFS in 2L metastatic PDAC","bullets":["Median PFS of 8.5 months (95% CI: 5.3-11.7) in 2L PDAC with KRAS G12X; 4.4 months in 3L+.","Median OS of 14.5 months in 2L PDAC; 6-month OS rate 89% (KRAS G12X) and 91% (broader RAS mutant).","ORR 29% (2L) and 22% (3L+); disease control rate 91% (2L) and 89% (3L+).","Safety: 98% any grade TRAEs, 29% Grade≥3; no discontinuations; mean dose intensity 92%.","Data cutoff July 23, 2024; 127 PDAC patients across 160-300 mg daily doses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-241397","json":"https://secwatch.observer/filing/0001193125-24-241397.json","markdown":"https://secwatch.observer/filing/0001193125-24-241397.md","text":"https://secwatch.observer/filing/0001193125-24-241397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524241397/0001193125-24-241397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524241397/d750511d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:06:16.891995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}